In September 2025, U.S. President Donald Trump’s sweeping announcement imposing a 100% tariff on branded and patented pharmaceutical imports from October 1, 2025, noticed India’s pharmaceutical enterprise, which has long been hailed as the “pharmacy of the world”, standing at a crossroads. The U.S.’s switch, ostensibly aimed toward bolstering home manufacturing, threatens to disrupt provide chains that have saved the U.S. health-care arrangement billions of bucks whereas furthermore fuelling India’s export-led boost.
But, as tariffs ripple thru global markets, India’s dominance in generics affords a actually predominant buffer, whilst it underscores the pressing want for diverse partnerships and home reforms. With pharma exports to the U.S. alone reaching discontinuance to $9 billion in fiscal 2025 — a 14.29% surge 300 and sixty five days-on-300 and sixty five days — the stakes is per chance now not bigger for India’s $50 billion pharmaceutical sector, which contributes virtually 1.72% to the nation’s GDP.
A world point of view
World pharmaceutical exports, valued at over $850 billion in 2024, thrive on aging populations, power ailments, and put up-COVID-19 pandemic innovation. Germany ($119.85 billion), Switzerland ($Ninety nine.08 billion), and the U.S. ($90.30 billion) had been lead exporters in 2023-24, whereas the U.S. ($212.67 billion in imports in 2024), Switzerland, Germany, Belgium, and China top importers. The European Union (EU)’s €313.4 billion in medicinal exports in 2024, up 13.5%, displays resilience amid geopolitical tensions. India, the third-ideal exporter by quantity, shipped $27 billion in 2023, rising to $30.47 billion in FY25.
Generics dominate, with 70% of exports to the U.S. and Europe. On the other hand, $5 billion in annual imports, essentially energetic pharmaceutical substances (API) from China (72% piece), exposes provide chain dangers. The sphere’s 10%-12% CAGR adds 0.5%-1% to GDP boost yearly, bolstering forex reserves. The U.S. tariff, which has spared generics for now, targets branded treatment unless made domestically. India supplies 40% of U.S. generics, saving payers $219 billion in 2022. But, the market jitters had been immediate with the shares of pharma majors falling and erasing hundreds and hundreds in market cap. An escalation to generics could well perhaps even cut export revenues by 10%-15%, trimming GDP boost by 0.2%-0.3% in FY26. Some corporations with over 30% U.S. publicity, face rerouting costs, regulatory hurdles, API inflation (up 5%-7%), and stalled analysis and pattern. This is in a position to well perhaps even spur “China-plus-one” suggestions, redirecting exports to Africa and Southeast Asia, doubtlessly raising India’s regulated market piece from 3% to some.5% by 2030.
Editorial | Weaponising health care: On the Trump tariffs on imported medicines
India’s Goods and Services Tax (GST) rationalisation, efficient September 22, 2025, affords home ballast. Drug and treatment rates dropped from 12% to 5%, with 36 predominant objects at nil, saving patrons $1.2 billion yearly. Clinical tool rates fell from 18% to 5%, easing $5 billion in imports. No re-labelling for pre-September stocks minimises disruptions. Aligned with Ayushman Bharat, this boosts consumption by 8%-10%, insulating markets from tariff-pushed hikes.
On jap scale
World alternate pits western innovation in opposition to jap scale. Beneath the U.S.-EU pact, EU exports of medicinal and pharmaceutical products to the U.S. ($65.7 billion from Eire in 2024), prioritises provide chain security. China’s 2025 agreements, taking pictures 32% of Q1 global biotech affords, and $2.5 billion in U.S. molecule licensing in H1 2025, designate jap energy. India’s diplomacy has seen the signing of six memoranda of figuring out (MoU) with Trinidad and Tobago in July 2025 (it involves cooperation in pharmaceuticals), a Singapore API pact, and Serum Institute’s dengue treatment collaboration for low-heart-profits countries. These, alongside iPHEX (the worldwide pharmaceutical exhibition) could well perhaps even double exports to Africa an excellent deal. With 35% of pharmaceutical exports U.S.-walk, jap alliances could well perhaps even offset 20%-25% of tariff dangers.
Bullish forecasts
Forecasts paint a bullish canvas: India’s pharma market, valued at $50 billion in 2023-24, has a aim of reaching $130 billion by 2030 (11%-12% CAGR), with exports surging to $120-$130 billion. Globally, spending could well perhaps even hit $1.5 trillion by 2029, fuelled by biosimilars and precision treatment. India’s API sector could well perhaps even develop to ₹1.82 trillion by 2030 ($22 billion), with PLI schemes reclaiming 20% home manufacturing.
Challenges equivalent to IP disputes and API dependency persist, however resilience shines thru initiatives equivalent to Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). Beneath the PMBJP, a entire of 16,912 Jan Aushadhi Kendras had been opened (June 2025), with 2,110 medicines and 315 surgicals, scientific consumables and gadgets below the arrangement product basket.
Tariffs threaten affordability, with U.S. most cancers treatment costs doubtlessly rising $8,000-$10,000 for a 24-week direction, mirroring India’s 60% out-of-pocket burden. Generics, 80% more cost-effective, enable 20 million treatments yearly, though quality concerns and disruptions risk delaying surgical procedures by 15%-20%. PMBJP’s oncology basket, cutting costs by 70%, proves that home buffers work.
U.S. tariffs risk causing shortages if India’s 40% generic provide frays. India have to leverage MoUs, invest $10 billion in APIs by potential of PLI 2.0, and push WTO reforms. With global pharma eyeing $450 billion for India by 2047, collaboration in the pick up of east-west hybrids, innovation, and equitable entry is predominant. Policymakers have to diversify boldly, reform snappy, and valid India’s pharma supremacy.
R.H. Pavithra is Professor, Department of Experiences and Compare in Economics, Karnataka Enlighten Initiate University, Mysuru, Karnataka
